Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved
the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend …

Recent years have witnessed increasingly rapid advances in nanocarrier-based
biomedicine aimed at improving treatment paradigms for cancer. Nanogels serve as …

Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses
in patients with many different types of cancer; however, most patients who receive ICB …

Antibody–drug conjugates (ADCs) have become a credentialled class of anticancer drugs
for both solid and hematological malignancies, with regulatory approvals mainly as single …

Multiple nanotherapeutics have been approved for patients with cancer, but their effects on
survival have been modest and, in some examples, less than those of other approved …

Nanogels, also termed hydrogel nanoparticles, have the properties and functions of both
nanomaterials and hydrogels. Till date, a considerable number of nanogels have been …

The highly immunosuppressive tumor microenvironment (TME) in solid tumors often
dampens the efficacy of immunotherapy. In this study, bacterial outer membrane vesicles …

Advances in the field of nanotechnology together with an increase understanding of tumor
immunology have paved the way for the development of more personalized cancer immuno …

Imidazoquinoline derivatives (IMDs) and related compounds function as synthetic agonists
of Toll-like receptors 7 and 8 (TLR7/8) and one is FDA approved for topical antiviral and skin …

The immune system is involved in the initiation and progression of cancer. Research on
cancer and immunity has contributed to the development of several clinically successful …